Models
BACIL PHARMA LTD.BSE 524516Pharmaceuticals & Biotechnology
₹16per share · Base Model Note
The horizon and scenarios are yours to change. Every other input is part of the Trader plan; saving, sharing a saved link and the live-formula workbook are part of the Institutional plan.
Scenario
Value per share, your model₹16implied P/B 0.88× on FY26 book
Against CMP ₹23.98−34.4%close of 9 Oct 2026
Cost of equity6.47%risk-free + beta × equity risk premium
Book equity, FY26₹18per share · excess returns add ₹(2)
This figure is the arithmetic of your inputs and nothing else. MarketPing publishes no fair value, target or rating; the model is yours.

Excess-return schedule · ₹ crore · book equity earns your ROE; value is book plus the returns above the cost of equity

₹ croreFY27FY28FY29FY30FY31
Opening book equity2527283032
Net income at 6.3% ROE22222
Cost of equity charge at 6.47%(2)(2)(2)(2)(2)
Excess return(0)(0)(0)(0)(0)
Present value(0)(0)(0)(0)(0)
Closing book equity2728303234
Book equity today25
PV of 5 years of excess return(0)
PV of the terminal excess return, 5% flat(3)
add non-operating investments0
Equity value22
÷ 1.40 crore shares₹16
ROE is at or below the cost of equity, so every year destroys value against book and the model lands below book value. That is the arithmetic, not a view.

Where the methods land · ₹ per share · the dashed line is the CMP

52-week rangetraded range, a fact not a value
₹11₹62

Scenarios side by side · ₹ per share

ScenarioTemplateGrowthMarginRateTerminal₹ / sharevs CMP
Base · editingExcess returnROE 6.3%—6.47%5%₹16(34.4)%
A scenario is a full set of inputs under a name. Keep Base as the filed history carried forward; add Bull and Bear by saving the current inputs under those names and moving the two or three assumptions you actually hold a view on. The distribution above draws each driver between the lowest and highest value across your scenarios, so three scenarios give it a real range; with one scenario it falls back to fixed bands.